Jak inhibitors in the treatment of alopecia areata - a literature review
DOI:
https://doi.org/10.12775/JEHS.2025.82.60104Keywords
JAK inhibiors, alopecia areata, barticitinib, ruxolitinib, topical JAK inhibitors, JAK/ STAT pathwayAbstract
Introduction
Alopecia areata (AA) is a chronic autoimmune disorder causing non-scarring hair loss, which can range from isolated patches to complete scalp (alopecia totalis, AT) or body hair loss (alopecia universalis, AU). It affects people of all ages, genders, and ethnicities. Around 10-20% of cases have a familial component, indicating a genetic predisposition. Symptoms often begin before age 40, with about half of patients experiencing onset in childhood, and it may coexist with other autoimmune diseases. The disease’s course is unpredictable, with spontaneous hair regrowth possible, though relapses are common, reaching a 100% relapse rate after 10-20 years. AA significantly affects quality of life, increasing the risk of anxiety and depression. Research has linked AA to autoimmune processes involving the JAK-STAT pathway, which promotes inflammation around hair follicles. Recent studies highlight the potential of JAK inhibitors as effective treatments.
Material and methods
An electronic literature search was performed using PubMed, Cochrane Library, and Evidence‑Based Medicine Reviews. Search terms included ‘alopecia areata’, ‘hair loss‘ , ‘JAK inhibitor’, ‘JAK-2 inhibitors’, ‘ Janus Kinase Inhibitors‘, ‘tofacitinib’, ruxolitinib’, ‘baricitinib’ as keywords. The review focused on articles published in English from their inception until 2025.
Conclusions
Janus kinase (JAK) inhibitors represent a significant advancement in treating alopecia areata by specifically targeting the JAK/STAT pathway, which is linked to hair loss. Oral JAK inhibitors like have shown the most promising results. However, challenges remain, including the risk of relapse after therapy, side effects, and limited efficacy of topical formulations. Ongoing research aims to develop more selective JAK inhibitors and maintenance strategies while addressing high treatment costs.
References
1. Haughton RD, Herbert SM, Ji-Xu A, Downing L, Raychaudhuri SP, Maverakis E. Janus kinase inhibitors for alopecia areata: A narrative review. Indian J Dermatol Venereol Leprol. 2023 Nov-Dec;89(6):799-806. doi: 10.25259/IJDVL_1093_2022. PMID: 37436019.
2. Villasante Fricke AC, Miteva M. Epidemiology and burden of alopecia areata: a systematic review. Clin Cosmet Investig Dermatol. 2015 Jul 24;8:397-403. doi: 10.2147/CCID.S53985. PMID: 26244028; PMCID: PMC4521674.
3. Goh C, Finkel M, Christos PJ, Sinha AA. Profile of 513 patients with alopecia areata: associations of disease subtypes with atopy, autoimmune disease and positive family history. J Eur Acad Dermatol Venereol. 2006 Oct;20(9):1055-60. doi: 10.1111/j.1468-3083.2006.01676.x. PMID: 16987257.
4. Trüeb RM, Dutra H, Dias MFRG. A Comment on JAK Inhibitors for Treatment of Alopecia Areata. Int J Trichology. 2018 Sep-Oct;10(5):193-197. doi: 10.4103/ijt.ijt_62_18. PMID: 30607037; PMCID: PMC6290291.
5. Toussi A, Barton VR, Le ST, Agbai ON, Kiuru M. Psychosocial and psychiatric comorbidities and health-related quality of life in alopecia areata: A systematic review. J Am Acad Dermatol. 2021 Jul;85(1):162-175. doi: 10.1016/j.jaad.2020.06.047. Epub 2020 Jun 17. PMID: 32561373; PMCID: PMC8260215.
6. Triyangkulsri K, Suchonwanit P. Role of janus kinase inhibitors in the treatment of alopecia areata. Drug Des Devel Ther. 2018 Jul 27;12:2323-2335. doi: 10.2147/DDDT.S172638. PMID: 30100707; PMCID: PMC6067625.
7. Stefanis AJ. Janus Kinase Inhibitors in the Treatment of Alopecia Areata. Prague Med Rep. 2023;124(1):5-15. doi: 10.14712/23362936.2023.1. PMID: 36763827.
8. Paus R, Ito N, Takigawa M, Ito T. The hair follicle and immune privilege. J Investig Dermatol Symp Proc. 2003 Oct;8(2):188-94. doi: 10.1046/j.1087-0024.2003.00807.x. PMID: 14582671.
9. Bertolini M, McElwee K, Gilhar A, Bulfone-Paus S, Paus R. Hair follicle immune privilege and its collapse in alopecia areata. Exp Dermatol. 2020 Aug;29(8):703-725. doi: 10.1111/exd.14155. PMID: 32682334.
10. Xing L, Dai Z, Jabbari A, Cerise JE, Higgins CA, Gong W, de Jong A, Harel S, DeStefano GM, Rothman L, Singh P, Petukhova L, Mackay-Wiggan J, Christiano AM, Clynes R. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med. 2014 Sep;20(9):1043-9. doi: 10.1038/nm.3645. Epub 2014 Aug 17. PMID: 25129481; PMCID: PMC4362521.
11. Stankler L. Synchronous alopecia areata in two siblings: a possible viral aetiology. Lancet. 1979 Jun 16;1(8129):1303-4. doi: 10.1016/s0140-6736(79)92271-2. PMID: 87773.
12. Colombe BW, Price VH, Khoury EL, Garovoy MR, Lou CD. HLA class II antigen associations help to define two types of alopecia areata. J Am Acad Dermatol. 1995 Nov;33(5 Pt 1):757-64. PMID: 7593774.
13. Ismail FF, Sinclair R. JAK inhibition in the treatment of alopecia areata - a promising new dawn? Expert Rev Clin Pharmacol. 2020 Jan;13(1):43-51. doi: 10.1080/17512433.2020.1702878. Epub 2019 Dec 22. PMID: 31865802.
14. McDonagh AJ, Tazi-Ahnini R. Epidemiology and genetics of alopecia areata. Clin Exp Dermatol. 2002 Jul;27(5):405-9. doi: 10.1046/j.1365-2230.2002.01077.x. PMID: 12190641.
15. Dillon KL. A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata. Clin Cosmet Investig Dermatol. 2021 Jun 25;14:691-714. doi: 10.2147/CCID.S309215. PMID: 34211288; PMCID: PMC8242127.
16. Fragoulis GE, McInnes IB, Siebert S. JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis. Rheumatology (Oxford). 2019 Feb 1;58(Suppl 1):i43-i54. doi: 10.1093/rheumatology/key276. PMID: 30806709; PMCID: PMC6390879.
17. Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O'Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017 Dec;16(12):843-862. doi: 10.1038/nrd.2017.201. Epub 2017 Nov 6. Erratum in: Nat Rev Drug Discov. 2017 Dec 28;17(1):78. doi: 10.1038/nrd.2017.267. PMID: 29104284.
18. Harel S, Higgins CA, Cerise JE, Dai Z, Chen JC, Clynes R, Christiano AM. Pharmacologic inhibition of JAK-STAT signaling promotes hair growth. Sci Adv. 2015 Oct 23;1(9):e1500973. doi: 10.1126/sciadv.1500973. PMID: 26601320; PMCID: PMC4646834.
19. Sardana K, Bathula S, Khurana A. Which is the Ideal JAK Inhibitor for Alopecia Areata - Baricitinib, Tofacitinib, Ritlecitinib or Ifidancitinib - Revisiting the Immunomechanisms of the JAK Pathway. Indian Dermatol Online J. 2023 Jun 28;14(4):465-474. doi: 10.4103/idoj.idoj_452_22. PMID: 37521227; PMCID: PMC10373824.
20. Liu LY, King BA. Tofacitinib for the Treatment of Severe Alopecia Areata in Adults and Adolescents. J Investig Dermatol Symp Proc. 2018 Jan;19(1):S18-S20. doi: 10.1016/j.jisp.2017.10.003. PMID: 29273099.
21. Zhang W, Li X, Chen B, Zhang J, Torres-Culala KMT, Zhou C. Oral Tofacitinib and Systemic Corticosteroids, Alone or in Combination, in Patients With Moderate-to-Severe Alopecia Areata: A Retrospective Study. Front Med (Lausanne). 2022 Jun 21;9:891434. doi: 10.3389/fmed.2022.891434. PMID: 35801202; PMCID: PMC9255896.
22. Olamiju B, Friedmann A, King B. Treatment of severe alopecia areata with baricitinib. JAAD Case Rep. 2019 Oct 22;5(10):892-894. doi: 10.1016/j.jdcr.2019.07.005. PMID: 31681829; PMCID: PMC6818396.
23. Lensing M, Jabbari A. An overview of JAK/STAT pathways and JAK inhibition in alopecia areata. Front Immunol. 2022 Aug 30;13:955035. doi: 10.3389/fimmu.2022.955035. PMID: 36110853; PMCID: PMC9470217.
24. King B, Ohyama M, Kwon O, Zlotogorski A, Ko J, Mesinkovska NA, Hordinsky M, Dutronc Y, Wu WS, McCollam J, Chiasserini C, Yu G, Stanley S, Holzwarth K, DeLozier AM, Sinclair R; BRAVE-AA Investigators. Two Phase 3 Trials of Baricitinib for Alopecia Areata. N Engl J Med. 2022 May 5;386(18):1687-1699. doi: 10.1056/NEJMoa2110343. Epub 2022 Mar 26. PMID: 35334197.
25. Mackay-Wiggan J, Jabbari A, Nguyen N, Cerise JE, Clark C, Ulerio G, Furniss M, Vaughan R, Christiano AM, Clynes R. Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata. JCI Insight. 2016 Sep 22;1(15):e89790. doi: 10.1172/jci.insight.89790. PMID: 27699253; PMCID: PMC5033756.
26. Bayart CB, DeNiro KL, Brichta L, Craiglow BG, Sidbury R. Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata. J Am Acad Dermatol. 2017 Jul;77(1):167-170. doi: 10.1016/j.jaad.2017.03.024. PMID: 28619556.
27. Craiglow BG, Tavares D, King BA. Topical Ruxolitinib for the Treatment of Alopecia Universalis. JAMA Dermatol. 2016 Apr;152(4):490-1. doi: 10.1001/jamadermatol.2015.4445. PMID: 26649829.
28. Bokhari L, Sinclair R. Treatment of alopecia universalis with topical Janus kinase inhibitors - a double blind, placebo, and active controlled pilot study. Int J Dermatol. 2018 Dec;57(12):1464-1470. doi: 10.1111/ijd.14192. Epub 2018 Aug 30. PMID: 30160787.
29. Steele L, Lee HL, Maruthappu T, O'Toole EA. The status and outcomes of registered clinical trials for Janus kinase inhibitors in alopecia areata: are unpublished trials being overlooked? Clin Exp Dermatol. 2021 Oct;46(7):1290-1292. doi: 10.1111/ced.14615. Epub 2021 Jul 14. PMID: 33608909.
30. Gilhar A, Keren A, Paus R. JAK inhibitors and alopecia areata. Lancet. 2019 Jan 26;393(10169):318-319. doi: 10.1016/S0140-6736(18)32987-8. PMID: 30696569.
31. Hoisnard L, Lebrun-Vignes B, Maury S, Mahevas M, El Karoui K, Roy L, Zarour A, Michel M, Cohen JL, Amiot A, Claudepierre P, Wolkenstein P, Grimbert P, Sbidian E. Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database. Sci Rep. 2022 May 3;12(1):7140. doi: 10.1038/s41598-022-10777-w. PMID: 35504889; PMCID: PMC9065106.
32. Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, Germino R, Menon S, Sun Y, Wang C, Shapiro AB, Kanik KS, Connell CA; ORAL Surveillance Investigators. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med. 2022 Jan 27;386(4):316-326. doi: 10.1056/NEJMoa2109927. PMID: 35081280.
33. Jorgensen SC, Tabbara N, Burry L. A review of COVID-19 therapeutics in pregnancy and lactation. Obstet Med. 2022 Dec;15(4):225-232. doi: 10.1177/1753495X211056211. Epub 2022 Jan 12. PMID: 36514791; PMCID: PMC9732495.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Paulina Krzeszowska, Aleksandra Kujawa, Karolina Krochmal, Wojciech Pisarek, Adrianna Samoraj, Jakub Zajączkowski, Kacper Stępniak, Jan Wilk, Karolina Marrodán-Wojtczak, Radosław Kuźma

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 222
Number of citations: 0